MedTrace Logo

Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (Australia)

NCT06225336 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2025-11-19

No results posted yet for this study

Summary

AUR-201 is indicated for the treatment of Grade II, III, or IV unilateral microtia in patients 8 to 29 years of age.

Conditions

  • Microtia

Interventions

COMBINATION_PRODUCT

AUR-201

Auricle and wedge subcutaneous implant consisting of 3-D printed autologous auricular sourced chondrocytes in a biopolymer matrix.

Sponsors & Collaborators

  • Auregen Biotherapeutics, SA

    lead INDUSTRY

Principal Investigators

  • Joseph Dusseldorp, MD · Chris O'Brien Lifehouse

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
8 Years
Max Age
29 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-04
Primary Completion
2025-09-10
Completion
2025-09-10

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06225336 on ClinicalTrials.gov